Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rapamycin for Renal Function in Heart Transplant
NCT00123331Phase 4Completed
- Sponsor
- Heidelberg University
- Start
- Oct 2003
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of sirolimus in heart transplant rejection (2 arms), sponsored by Heidelberg University. Primary endpoint: Renal function (serum creatinine, calculated creatinine clearance) at 6 months. Started Oct 2003; status: completed.
02
Drugs
sirolimus
03
Conditions
heart transplant rejection
Beyond the preview
Go deeper on NCT00123331.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00123331.